Results 61 to 70 of about 18,687 (213)
Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia
Haemophilia, Volume 32, Issue 3, Page 584-592, May/June 2026.ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh +5 more
wiley +1 more source
mBio, 2018 Darunavir (DRV) has bimodal activity against HIV-1 protease, enzymatic inhibition and protease dimerization inhibition, and has an extremely high genetic barrier against development of drug resistance. We previously generated a highly DRV-resistant HIV-1
Manabu Aoki +6 more
doaj +1 more source
Journal of Pharmacy and Bioallied Sciences, 2021 Aims and Objective: The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form. Materials and Methods: The chromatographic separation was achieved
Sabyasachi Biswal +2 more
doaj +1 more source
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeks [PDF]
, 2012 We assessed metabolic changes for darunavir/ritonavir (DRV/r) once daily (qd) versus atazanavir/ritonavir (ATV/r) qd with fixed-dose tenofovir/emtricitabine. This was a phase 4, multicenter, open-label, randomized exploratory study.
Aberg, Judith A +8 more
core +2 more sources
HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito +13 more
wiley +1 more source
Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
HIV/AIDS: Research and Palliative Care, 2016 Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is
Navarro J, Curran A
doaj
Brazilian Journal of Infectious Diseases, 2013 Objectives: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil.
José Ernesto Vidal +11 more
doaj +1 more source
HIV Research & Clinical Practice, 2020 Antiretroviral therapies have been tested with the goal of maintaining virological suppression with a particular attention in limiting drug-related toxicity.
Valentina Di Cristo +14 more
doaj +1 more source
Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART [PDF]
, 2015 Peer reviewedPublisher ...
Baguley, Steve +5 more
core
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens [PDF]
, 2017 López-Cortés, Luis F. et al.[Background and Objective] Significant controversy still exists about ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now to treat patients that have not experienced ...
López-Cortés, Luis F. +2 more
core +1 more source